What is CAM2029

What is CAM2029

CAM2029 is a new investigational, long-acting (depot) formulation containing the well-established ingredient octreotide, which is under development for the treatment of acromegaly. CAM2029 is being tested in clinical trials and is not commercially approved.

The acromegaly treatment option, CAM2029, is supplied in a prefilled syringe with a short 22 G needle or a pre-filled pen which allows auto injection where the needle is not visible. Both configurations are ready to use. It is administered under the skin (subcutaneous) by the doctor or by the subject or by their partner, after appropriate training.

The investigational medication for acromegaly, CAM2029 has been tested in healthy volunteers and subjects in early stage clinical trials.